NASDAQ:ESPR - Esperion Therapeutics Stock Price, Forecast & News

Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ESPR stock has decreased by 17.8% and is now trading at $35.29. View which stocks have been mosted impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 5 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Esperion Therapeutics.

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Esperion Therapeutics.

Esperion Therapeutics Inc (NASDAQ:ESPR) released its earnings results on Thursday, February, 27th. The biopharmaceutical company reported ($2.26) earnings per share for the quarter, beating the consensus estimate of ($2.67) by $0.41. The biopharmaceutical company had revenue of $0.98 million for the quarter, compared to analysts' expectations of $0.99 million. Esperion Therapeutics had a negative return on equity of 98.94% and a negative net margin of 65.49%. The firm's revenue was up 9819999999.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($2.24) earnings per share. View Esperion Therapeutics' earnings history.

12 brokers have issued 1-year price objectives for Esperion Therapeutics' shares. Their forecasts range from $45.00 to $191.00. On average, they expect Esperion Therapeutics' share price to reach $90.73 in the next twelve months. This suggests a possible upside of 157.1% from the stock's current price. View analysts' price targets for Esperion Therapeutics.

News coverage about ESPR stock has been trending negative on Sunday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Esperion Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutEsperion Therapeutics.

Esperion Therapeutics saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 6,209,100 shares, a drop of 9.4% from the February 27th total of 6,850,000 shares. Based on an average daily volume of 862,900 shares, the days-to-cover ratio is currently 7.2 days. Approximately 23.8% of the shares of the company are sold short. View Esperion Therapeutics' Current Options Chain.

Some companies that are related to Esperion Therapeutics include United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Evotec (EVTCY), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Emergent Biosolutions (EBS), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Genmab A/S (GMAB), Ultragenyx Pharmaceutical (RARE) and PPD (SDGR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include Alon USA Partners (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), Ship Finance International (SFL), NVIDIA (NVDA), Micron Technology (MU), BioMarin Pharmaceutical (BMRN), Alibaba Group (BABA), Gilead Sciences (GILD) and NXP Semiconductors (NXPI).

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Esperion Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (4.03%), Credit Suisse AG (3.25%), Rhenman & Partners Asset Management AB (2.42%), Goldman Sachs Group Inc. (1.49%), Geode Capital Management LLC (1.27%) and Amundi Pioneer Asset Management Inc. (1.20%). Company insiders that own Esperion Therapeutics stock include Boxer Capital, Llc, Nicole Vitullo, Richard Bartram, Roger S Newton, Target N V Biotech and Timothy M Mayleben. View institutional ownership trends for Esperion Therapeutics.

ESPR stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., State Street Corp, Nuveen Asset Management LLC, Credit Suisse AG, Rafferty Asset Management LLC, Spark Investment Management LLC, Oxford Asset Management LLP, and Alliancebernstein L.P.. View insider buying and selling activity for Esperion Therapeutics.

ESPR stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Rothschild & Co. Asset Management US Inc., Candriam Luxembourg S.C.A., Moody Aldrich Partners LLC, Goldman Sachs Group Inc., AXA, Sei Investments Co., and Man Group plc. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech, and Timothy M Mayleben. View insider buying and selling activity for Esperion Therapeutics.

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ESPR stock can currently be purchased for approximately $35.29.

Esperion Therapeutics has a market capitalization of $970.83 million and generates $148.36 million in revenue each year. The biopharmaceutical company earns $-97,170,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Esperion Therapeutics employs 76 workers across the globe. View additional information about Esperion Therapeutics.

The official website for Esperion Therapeutics is http://www.esperion.com/.

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]